相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
招募中
1
100.0%
暂无批准数据
- Six Australian biomedical and health tech startups will share A$13.5 million from the second investment round of the MRFF-backed CUREator+ commercialisation program. - Aleris Therapeutics, Frontier Inflammasome Therapeutics and Luma Bio each received A$2.5 million, spanning inflammatory disease, oncology and targeted cancer imaging. - Navier Medical received A$2.13 million for its AI-enabled Navier Heart platform, which analyses routine CT scans to predict and prevent heart attacks. - Neurotologix and WeGuide each received A$1.95 million to advance vertigo assessment and AI-powered digital biomarker development, respectively.
- Brandon Capital has launched the second funding round for its CUREator+ Dementia and Cognitive Decline incubator program, offering up to $5 million per project to support innovative dementia solutions. - The program targets the development of therapeutics, diagnostics, medical devices, and digital health technologies for Australia's 433,300 dementia patients and 1.7 million caregivers. - Funded by Australia's Medical Research Future Fund, the initiative provides non-dilutive grants through a competitive merit-based process with applications closing July 10, 2025. - Eligible projects span early diagnosis, progression prevention, symptom management, and quality of life improvements across preclinical, clinical, and commercial development stages.
